Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy

Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclea...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1146651
Main Authors Sun, Huiyan, Chen, Dandan, Xin, Wenjing, Ren, Lixue, LI, Qiang, Han, Xuchen
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 13.04.2023
Subjects
bioactive compounds
cardiomyopathies
ferroptosis
ferroptosis inhibitor
Pharmacology
treatment
treatment
bioactive compounds
ferroptosis
cardiomyopathies
ferroptosis inhibitor
Online AccessGet full text

Cover

More Information
Summary:Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclear. Emerging studies have demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by iron dyshomeostasis and lipid peroxidation, contributes to the development of ischemic cardiomyopathy, diabetic cardiomyopathy, doxorubicin-induced cardiomyopathy, and septic cardiomyopathy. Numerous compounds have exerted potential therapeutic effects on cardiomyopathies by inhibiting ferroptosis. In this review, we summarize the core mechanism by which ferroptosis leads to the development of these cardiomyopathies. We emphasize the emerging types of therapeutic compounds that can inhibit ferroptosis and delineate their beneficial effects in treating cardiomyopathies. This review suggests that inhibiting ferroptosis pharmacologically may be a potential therapeutic strategy for cardiomyopathy treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Yafeng Li, The Fifth Hospital of Shanxi Medical University, China
Edited by: Shusheng Wang, Tulane University, United States
These authors have contributed equally to this work
Reviewed by: Yao Tong, Tulane University, United States
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1146651